Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
(4) - EconoTimes)
CAMBRIDGE, Mass., April 05, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, granted an equity award on April 3, 2017 to Catherine Stehman-Breen. The award was previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to Dr. Stehman-Breen’s employment as chief medical officer. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Dr. Stehman-Breen received options to purchase 100,000 shares of Sarepta's common stock. The options have an exercise price of $29.70 per share, which is equal to the closing price of Sarepta's common stock on April 3, 2017. One-fourth of the shares underlying the employee’s option will vest on the one year anniversary of her date of hire and thereafter 1/48th of the shares underlying the option will vest monthly, such that the shares underlying the option will be fully vested on the fourth anniversary of her date of hire, in each case, subject to her continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit us at www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
